We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Struble and McAsey propose that apolipoprotein E (APOE) is a pivotal required intermediary in the neuroprotective effects of hormone replacement therapy (HT) not only in dementia but in other chronic neurological diseases. Basic science analyses indicate that 17β-estradiol increases APOE expression, which facilitates neuronal plasticity, neural repair, and could delay progression of several types of neurodegenerative disease. The issue of the APOE4 isoform, which may be a negative regulator of HT outcomes, is considered along with therapeutic implications for either increasing or decreasing its expression. These authors propose that subsequent studies of the impact of HT or selective estrogen receptor modulators on neurological function should include APOE genotyping.